경구 경점막 약물 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

The global Oral Transmucosal Drugs market is forecasted to grow at a noteworthy CAGR of 6.98% between 2025 and 2033. By 2033, market size is expected to surge to USD 75.48 Billion, a substantial rise from the USD 41.12 Billion recorded in 2024.

The global oral transmucosal drugs market is poised for growth driven by increasing demand for non-invasive, rapid-onset drug delivery systems. Oral transmucosal routes, including buccal and sublingual, offer advantages such as bypassing first-pass metabolism and improving patient compliance. Future developments will focus on novel formulations, mucoadhesive technologies, and nanocarrier systems to enhance bioavailability and therapeutic efficacy.

Moreover, rising prevalence of chronic pain, neurological disorders, and cardiovascular diseases is expanding application areas. Advances in drug delivery devices and personalized medicine are further propelling market growth. Regulatory frameworks supporting innovative delivery systems are facilitating commercialization. As patient-centric therapies gain prominence, the oral transmucosal drugs market will continue to innovate, delivering effective, convenient, and safe treatment options.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Oral Transmucosal Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product Type

• Tablets
• Films
• Liquid & Spray
• Other Product Types

By Route Of Administration

• Sublingual Mucosa
• Buccal Mucosa
• Other Routes Of Administration

By Indication

• Opioid Dependence
• Nausea And Vomiting
• Erectile Dysfunction
• Neurological Disorders
• Other Indications

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• List of Companies Profiled in the report
• Aquestive Therapeutics Inc., C.L.Pharm Co. Ltd., Cure Pharmaceutical, IntelGenx Technologies Corp, Jazz Pharmaceuticals plc, NAL Pharma, Novartis AG, Pfizer Inc., Teva Pharmaceutical Industries Limited, ZIM Laboratories Limited.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. ORAL TRANSMUCOSAL DRUGS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product Type
  • 3.7.2 Market Attractiveness Analysis By Route Of Administration
  • 3.7.3 Market Attractiveness Analysis By Indication
  • 3.7.4 Market Attractiveness Analysis By Distribution Channel
  • 3.7.5 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY PRODUCT TYPE

• 5.1. Overview By Product Type
• 5.2. Historical and Forecast Data Analysis By Product Type
• 5.3. Tablets Historic and Forecast Sales By Regions
• 5.4. Films Historic and Forecast Sales By Regions
• 5.5. Liquid & Spray Historic and Forecast Sales By Regions
• 5.6. Other Product Types Historic and Forecast Sales By Regions

6. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY ROUTE OF ADMINISTRATION

• 6.1. Overview By Route Of Administration
• 6.2. Historical and Forecast Data Analysis By Route Of Administration
• 6.3. Sublingual Mucosa Historic and Forecast Sales By Regions
• 6.4. Buccal Mucosa Historic and Forecast Sales By Regions
• 6.5. Other Routes Of Administration Historic and Forecast Sales By Regions

7. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY INDICATION

• 7.1. Overview By Indication
• 7.2. Historical and Forecast Data Analysis By Indication
• 7.3. Opioid Dependence Historic and Forecast Sales By Regions
• 7.4. Nausea And Vomiting Historic and Forecast Sales By Regions
• 7.5. Erectile Dysfunction Historic and Forecast Sales By Regions
• 7.6. Neurological Disorders Historic and Forecast Sales By Regions
• 7.7. Other Indications Historic and Forecast Sales By Regions

8. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1. Overview By Distribution Channel
• 8.2. Historical and Forecast Data Analysis By Distribution Channel
• 8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
• 8.4. Retail Pharmacies Historic and Forecast Sales By Regions
• 8.5. Online Pharmacies Historic and Forecast Sales By Regions

9. GLOBAL ORAL TRANSMUCOSAL DRUGS MARKET ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook
• 9.2. Introduction
• 9.3. North America Sales Analysis
  • 9.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.3.2 North America By Segment Sales Analysis
  • 9.3.3 North America By Country Sales Analysis
  • 9.3.4 United States Sales Analysis
  • 9.3.5 Canada Sales Analysis
  • 9.3.6 Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.4.2 Europe By Segment Sales Analysis
  • 9.4.3 Europe By Country Sales Analysis
  • 9.4.4 United Kingdom Sales Analysis
  • 9.4.5 France Sales Analysis
  • 9.4.6 Germany Sales Analysis
  • 9.4.7 Italy Sales Analysis
  • 9.4.8 Russia Sales Analysis
  • 9.4.9 Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.5.2 Asia Pacific By Segment Sales Analysis
  • 9.5.3 Asia Pacific By Country Sales Analysis
  • 9.5.4 China Sales Analysis
  • 9.5.5 India Sales Analysis
  • 9.5.6 Japan Sales Analysis
  • 9.5.7 South Korea Sales Analysis
  • 9.5.8 Australia Sales Analysis
  • 9.5.9 South East Asia Sales Analysis
  • 9.5.10 Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.6.2 Latin America By Segment Sales Analysis
  • 9.6.3 Latin America By Country Sales Analysis
  • 9.6.4 Brazil Sales Analysis
  • 9.6.5 Argentina Sales Analysis
  • 9.6.6 Peru Sales Analysis
  • 9.6.7 Chile Sales Analysis
  • 9.6.8 Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 9.7.2 Middle East & Africa By Segment Sales Analysis
  • 9.7.3 Middle East & Africa By Country Sales Analysis
  • 9.7.4 Saudi Arabia Sales Analysis
  • 9.7.5 UAE Sales Analysis
  • 9.7.6 Israel Sales Analysis
  • 9.7.7 South Africa Sales Analysis
  • 9.7.8 Rest Of Middle East And Africa Sales Analysis

10. COMPETITIVE LANDSCAPE OF THE ORAL TRANSMUCOSAL DRUGS COMPANIES

• 10.1. Oral Transmucosal Drugs Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11. COMPANY PROFILES OF ORAL TRANSMUCOSAL DRUGS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Aquestive Therapeutics Inc.
  • 11.3.1 Company Overview
  • 11.3.2 Company Revenue
  • 11.3.3 Products
  • 11.3.4 Recent Developments
• 11.4. C.L.Pharm Co. Ltd.
  • 11.4.1 Company Overview
  • 11.4.2 Company Revenue
  • 11.4.3 Products
  • 11.4.4 Recent Developments
• 11.5. Cure Pharmaceutical
  • 11.5.1 Company Overview
  • 11.5.2 Company Revenue
  • 11.5.3 Products
  • 11.5.4 Recent Developments
• 11.6. IntelGenx Technologies Corp
  • 11.6.1 Company Overview
  • 11.6.2 Company Revenue
  • 11.6.3 Products
  • 11.6.4 Recent Developments
• 11.7. Jazz Pharmaceuticals Plc
  • 11.7.1 Company Overview
  • 11.7.2 Company Revenue
  • 11.7.3 Products
  • 11.7.4 Recent Developments
• 11.8. NAL Pharma
  • 11.8.1 Company Overview
  • 11.8.2 Company Revenue
  • 11.8.3 Products
  • 11.8.4 Recent Developments
• 11.9. Novartis AG
  • 11.9.1 Company Overview
  • 11.9.2 Company Revenue
  • 11.9.3 Products
  • 11.9.4 Recent Developments
• 11.10. Pfizer Inc.
  • 11.10.1 Company Overview
  • 11.10.2 Company Revenue
  • 11.10.3 Products
  • 11.10.4 Recent Developments
• 11.11. Teva Pharmaceutical Industries Limited
  • 11.11.1 Company Overview
  • 11.11.2 Company Revenue
  • 11.11.3 Products
  • 11.11.4 Recent Developments
• 11.12. ZIM Laboratories Limited
  • 11.12.1 Company Overview
  • 11.12.2 Company Revenue
  • 11.12.3 Products
  • 11.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies